Chatter about a possible spinout for Siemens Healthcare (NYSE:SI) ramped up yesterday on a report from "2 people familiar with the plans" who said the German conglomerate is actively investigating a possible sale of its hospital database and IT business.
Siemens is evaluating options for the business but no final decision has yet been made, the unnamed sources told Bloomberg, with 1 noting that the IT unit could fetch more than €1 billion, or about $1.36 billion.
In May Siemens unveiled a massive reboot, flattening its businesses, eliminating a layer of management at the sector level and consolidating its 16 divisions into 9. Siemens also said it plans to spin out its 4,000-employee hearing aid business into a public company as part of the move, dubbed "Vision 2020."
The announcement may have signaled Siemens’ spinout intentions regarding Siemens Healthcare, which reported profits of €531 million ($739.6 million), on sales of €3.26 billion during the 3 months ended March 31, for profit growth of 19.3% on a sales decline of -0.7%.
A Siemens spokesman declined to comment, the news service reported.
480 Biomedical wins $1M NHLBI grant for pediatric stent
480 Biomedical yesterday said it won $1 million in Phase II funding from the National Heart, Lung, & Blood Institute for the development of a bioresorbable, self-expanding scaffold to treat pediatric pulmonary artery stenosis, saying it plans to use the proceeds to refine the stent’s design and run pre-clinical testing.
Study: GPOs generate $55B a year in healthcare savings
Group purchasing organizations generate up to $55 billion in savings each year for hospitals, Medicare & Medicaid and taxpayers, according to a study by the Healthcare Supply Chain Assn. and healthcare economists Dobson DaVanzo & Assoc. From 2013 to 2022, GPOs are expected to generate savings of up to $864 billion for the entire U.S. health system, $229 billion in Medicare savings and $169 billion in Medicaid savings, according to the study, which used National Health Expenditure data published by the U.S. Centers for Medicare & Medicaid Services.
Ireland hates inversions too
Ireland’s top lawmakers aren’t too psyched about the welter of so-called "inversion deals" that have surfaced lately – most notably Medtronic’s $43 bid for Covidien – by U.S. companies looking to enjoy its low, 12.5% corporate tax rate. That’s because inversions are eroding the revenue base on the Emerald Isle, for which the new tax revenue is about the only economic benefit. The rub is that foreign companies domiciled there do count toward its gross national product, which is in turn used to calculate Ireland’s contribution to the European Union.
McKesson Medical-Surgical to distribute the Femasys Femcerv device
Femasys said this week that it inked a deal with McKesson Medical-Surgical to distribute Femasys’ Femcerv endocervical biopsy device.